Shanghai Annova Biotechnology Co. Ltd. has disclosed substituted fused heterocyclic compounds acting as ATR kinase inhibitors reported to be useful for the treatment of cancer.
Ceralasertib is an oral selective inhibitor of the ATR kinase, an important DNA-repairing protein in tumor cells.
Cryo-EM reconstructions of the human ATR–ATRIP complex show how clinical small-molecule inhibitors like VE-822 and RP-3500 bind to and inhibit ATR activity. A research team led by Prof. Gang Cai and ...
Researchers from Antengene Biologics Ltd. and Shanghai Antengene Corp. Ltd. have identified ATR kinase inhibitors reported to be useful for the treatment of cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback